CCN2 and pulmonary fibrosis: While to date there have been no human trials specifically studying the role of anti-CCN2 therapy on extraneural fibrosis, a comparison of restrictive soft tissue effects can be made with studies in pulmonary fibrosis where anti-CCN2 therapy attenuates functional declines by decreasing interstitial lung fibrosis [28].